Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents

  • Jingwei Jiang
  • Xiaohua Liang
  • Xinli Zhou
  • Ruofan Huang
  • Zhaohui Chu
  • Qiong Zhan
Original Paper

Abstract

Purpose

The aim was to compare the efficacy between doublets of third-generation agents (non-platinum) and doublets of platinum plus a third-generation agent (platinum-based) for chemotherapy-naïve advanced non-small-cell lung cancer (NSCLC).

Methods

We conducted a literature-based meta-analysis to compare the efficacy between doublets of third-generation agents and doublets of platinum plus a third-generation agent for chemotherapy-naïve advanced NSCLC. The primary end point was overall survival, and the secondary end points were progression-free survival (PFS) and response rate. Subgroup analyses were also conducted by different non-platinum doublet regimens or different platinum-based doublets. A descriptive review for toxicity was performed.

Results

Sixteen randomized controlled trials were identified ultimately. Results demonstrated that the efficacy of non-platinum doublets was comparable with platinum-based doublets according to the overall survival (HR = 1.03, 95 % CI = 0.98–1.08, p = 0.29). Subgroup analyses by different non-platinum doublets also showed the efficacy of all the third-generation doublets, such as vinorelbine plus gemcitabine, vinorelbine plus paclitaxel, gemcitabine plus paclitaxel, and gemcitabine plus docetaxel, was comparable with platinum-based doublets (HR = 1.00, 95 % CI = 0.78–1.27, p = 0.98; HR = 0.97, 95 % CI = 0.80–1.18, p = 0.79; HR = 1.05, 95 % CI = 0.99–1.12, p = 0.11; HR = 1.01, 95 % CI = 0.92–1.10, p = 0.87; respectively). Subgroup analyses by different platinum-based doublets indicated that the efficacy of the third-generation doublets were equal to both cisplatin-based doublets and carboplatin-based doublets (HR = 1.08, 95 % CI = 1.00–1.17, p = 0.05; HR = 1.00, 95 % CI = 0.94–1.05, p = 0.94; respectively). The secondary end points indicated that platinum-based doublets might have an advantage in PFS but not in response rate (HR = 1.06, 95 % CI = 1.01–1.12, p = 0.03; RR = 0.99, 95 % CI = 0.90–1.08, p = 0.81; respectively).

Conclusions

Non-platinum doublets were as effective as platinum-based doublets with different toxicity profile for chemotherapy-naïve advanced NSCLC in the era of third-generation agents.

Keywords

Carcinoma Non-small-cell lung Chemotherapy Platinum Third-generation agents Meta-analysis 

References

  1. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857PubMedCrossRefGoogle Scholar
  2. Azzoli CG, Baker SJ, Temin S, Pao W, Aliff T, Brahmer J et al (2009) American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251–6266PubMedCrossRefGoogle Scholar
  3. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2:845–853PubMedCrossRefGoogle Scholar
  4. Barata FJ, Parente B, Cunha J, Fernandes A, Figueiredo A, Conde S et al (2002) A phase II study, multicenter, randomized of carboplatin plus gemcitabine (CG) versus vinorelbine plus gemcitabine (VG) in advanced non small cell lung cancer (NSCLC) [abstract]. ESMO annual meeting. 523 pGoogle Scholar
  5. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  6. Chen YM, Perng RP, Lee YC, Shih JF, Lee CS, Tsai CM et al (2002) Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann Oncol 13:108–115PubMedCrossRefGoogle Scholar
  7. Chen S, Zhang J, Wang R, Luo X, Chen H (2010) The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis. Lung Cancer 70:63–70PubMedCrossRefGoogle Scholar
  8. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA (2005) Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23:2926–2936PubMedCrossRefGoogle Scholar
  9. D’Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E (2010) ESMO Guidelines Working Group. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):S116–S119CrossRefGoogle Scholar
  10. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  11. Fløtten Ø, Bremnes RM, Grønberg BH, Sundstrøm S, Amundsen T, Rolke H et al (2010) Phase III study comparing vinorelbine/gemcitabine with vinorelbine/carboplatin as first-line chemotherapy of advanced NSCLC: a Norwegian Lung Cancer Study Group trial [abstract]. J Clin Oncol 15(suppl): abstr 7597Google Scholar
  12. Galvez C, Galmarini F (2000) Gemcitabine/cisplatin (G/P) vs gemcitabine/vinorelbine (G/V) in the treatment of non-small cell lung cancer (NSCLC): stage IIIB and IV abstract]. Ann Oncol 11(suppl 4):S115 (abstr 526P)Google Scholar
  13. Gamaz M, Taright TMS (2006) Gemcitabine/docetaxel (GD) versus gemcitabine/cisplatin (GC) in stage III/IV non-small cell lung cancer (NSCLC): preliminary results [abstract]. ASCO Annual Meeting Proceedings Part I 24(18S): abstr 17116Google Scholar
  14. Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A et al (2001a) Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 34(Suppl 4):S47–S51PubMedCrossRefGoogle Scholar
  15. Georgoulias V, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, Veslemes M et al (2001b) Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial. Lancet 357:1478–1484PubMedCrossRefGoogle Scholar
  16. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O et al (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 23:2937–2945PubMedCrossRefGoogle Scholar
  17. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF et al (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21:3025–3034PubMedCrossRefGoogle Scholar
  18. Grossi F, Aita M, Defferrari C, Rosetti F, Brianti A, Fasola G et al (2009) Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist 14:497–510PubMedCrossRefGoogle Scholar
  19. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560PubMedCrossRefGoogle Scholar
  20. Iwamoto Y, Saito H, Nakagawa K, Kashii T, Katakami N, Nakano T, et al (2007) A randomized phase II study of carboplatin and paclitaxel (CP) versus gemcitabine and vinorelbine (GV) in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): West Japan Thoracic Oncology Group 00 [abstract]. ASCO Annual Meeting Proceedings Part I 25(18S): abstr 18060Google Scholar
  21. Jahnke K, Keilholz U, Luftner D, Thiel E, Schmittel A (2011) Randomized phase II study of paclitaxel and carboplatin or vinorelbine in advanced non-small cell lung cancer. Anticancer Res 31:317–323PubMedGoogle Scholar
  22. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRefGoogle Scholar
  23. Jiang J, Liang X, Zhou X, Huang R, Chu Z (2007) A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 57:348–358PubMedCrossRefGoogle Scholar
  24. Julian PTH, Douglas GA, Jonathan ACS (updated March 2011) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0. http://www.cochrane-handbook.org. Accessed 10 Feb 2012
  25. Katakami N, Takiguchi Y, Yoshimori K, Isobe H, Bessho A, Yoshimura A et al (2006) Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 1:447–453PubMedCrossRefGoogle Scholar
  26. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J et al (2002) Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 20:3578–3585PubMedCrossRefGoogle Scholar
  27. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D et al (2008) Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann Oncol 19:115–122PubMedCrossRefGoogle Scholar
  28. Lilenbaum RC, Chen CS, Chidiac T, Schwarzenberger PO, Thant M, Versola M et al (2005) Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer. Ann Oncol 16:97–101PubMedCrossRefGoogle Scholar
  29. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899–909CrossRefGoogle Scholar
  30. Novello S, Le Chevalier T (2003) Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology 17:357–364PubMedGoogle Scholar
  31. Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834PubMedCrossRefGoogle Scholar
  32. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF et al (2005) Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 16:602–610PubMedCrossRefGoogle Scholar
  33. Rigas JR, Carey M, Dragnev KH, Simeone SA, Page RD, Rubin MS et al (2008) Phase III multicenter web-based study demonstrating survival equivalents of nonplatinum-based chemotherapy for advanced non-small cell lung cancer (NSCLC): subgroup analysis from D0112 [abstract]. J Clin Oncol 26(15suppl): abstr 8100Google Scholar
  34. Rubio JC, Vazquez S, Vazquez F, Amenedo M, Fírvida JL, Mel JR et al (2009) A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma. Cancer Chemother Pharmacol 64:379–384PubMedCrossRefGoogle Scholar
  35. Smit EF, van Meerbeeck JP, Lianes P, Debruyne C, Legrand C, Schramel F et al (2003) Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group–EORTC 08975. J Clin Oncol 21:3909–3917PubMedCrossRefGoogle Scholar
  36. Solomon B, Bunn PA Jr (2005) Gemcitabine plus docetaxel for advanced or metastatic non-small cell lung cancer: similar survival to cisplatin plus vinorelbine and less toxicity. Cancer Treat Rev 31:571–576PubMedCrossRefGoogle Scholar
  37. Stathopoulos GP, Veslemes M, Georgatou N, Antoniou D, Giamboudakis P, Katis K et al (2004) Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial. Ann Oncol 15:1048–1055PubMedCrossRefGoogle Scholar
  38. Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K et al (2005) Randomized study of vinorelbine–gemcitabine versus vinorelbine–carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 49:233–240PubMedCrossRefGoogle Scholar
  39. Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM et al (2010) A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Ann Oncol 21:540–547PubMedCrossRefGoogle Scholar
  40. Walling J (1994) Chemotherapy for advanced non-small-cell lung cancer. Respir Med 88(649–657):18Google Scholar
  41. Yamamoto N, Nakagawa K, Uejima H, Sugiura T, Takada Y, Negoro S et al (2006) West Japan Thoracic Oncology Group (WJTOG). Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104. Cancer 107:599–605PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2012

Authors and Affiliations

  • Jingwei Jiang
    • 1
    • 2
  • Xiaohua Liang
    • 1
    • 2
  • Xinli Zhou
    • 1
    • 2
  • Ruofan Huang
    • 1
    • 2
  • Zhaohui Chu
    • 1
    • 2
  • Qiong Zhan
    • 1
    • 2
  1. 1.Department of Oncology, Huashan HospitalFudan UniversityShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina

Personalised recommendations